-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 10, Haisco announced that the company has recently received the "Notice of Approval for Clinical Trials of Drugs" issued by the State Food and Drug Administration
According to the "Pharmaceutical Administration Law of the People's Republic of China" and relevant regulations, after review, HSK36273 for injection accepted by the State Food and Drug Administration in January 2022 met the relevant requirements for drug registration, and was approved to carry out "systemic treatment for hemodialysis and intraoperative patients.
HSK36273 for injection is an intravenous anticoagulant drug developed by Hisco.